One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Akebia Therapeutics logo
Akebia Therapeutics AKBA
$ 0.39 -7.14%
report update icon

Quarterly report 2026-Q3
added 11-05-2026

Akebia Therapeutics Cash Flow 2025-2011 | AKBA

Brief overview of Akebia Therapeutics's cash generation

This overview follows the five latest available annual observations in the 2021–2025 interval.

Cash generation recovered from an outflow of -$253 million to positive operating cash flow of $68 million.

Operating cash flow was positive in only 1 of five periods. Cash generation remains unstable.

Estimated working capital fell by $13.2 million, releasing resources equal to about 5.6% of latest revenue.

Overall assessment

Akebia Therapeutics's cash flow is not clear-cut. Operating receipts exist, but their stability or the residual after investment needs attention.

Annual Cash Flow Akebia Therapeutics

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Operating Cash Flow

68 M -40.7 M -23.4 M -73.2 M -253 M -110 M -257 M -97.5 M -56.2 M 57.9 M - - - - -

Depreciation & Amortization

1.27 M 1.46 M 1.58 M 1.65 M 1.93 M 2.08 M 2.24 M 899 K 617 K 296 K 96 K 49 K 1 K - -

Accounts Payables

21.2 M 15.2 M 14.6 M 18 M 33.6 M 41.3 M 39.2 M 42.8 M 7 M 2.04 M 2.31 M 2.02 M - - -

Accounts Receivables

47 M 34.4 M 39.3 M 40.3 M 51.6 M 26.9 M 38.9 M 16.7 M 34.2 M - - 48 K - - -

Total Inventories

15.6 M 16.2 M 15.7 M 21.6 M 36.6 M 61 M 116 M 114 M - - - - - - -

All numbers in USD currency

Quarterly Cash Flow Akebia Therapeutics

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Operating Cash Flow

- 3.52 M -21.2 M 31.1 M 28.1 M 22.3 M -13.6 M -4.47 M -6.7 M -10.1 M -19.4 M -2.31 M -7.17 M 3.63 M -17.5 M -54.7 M 33.8 M -30.7 M -21.6 M -62.8 M -56.3 M -63.1 M -70.7 M -30.8 M -27.2 M 37.2 M -89.6 M -92.1 M 11 M -38.4 M -138 M -73.7 M -12.5 M 9 M -20.3 M -16.4 M -54.6 M 14.8 M - - - - - - - - - - - - - - - - - - - - - - - - -

Depreciation & Amortization

- 585 K 328 K - - - 314 K 9.01 M 9 M 9 M 9.01 M 9.01 M 9 M 9 M 9.01 M 9.01 M 9 M 9 M 9.01 M 9.01 M 9 M 9 M 9.01 M 8.31 M 6.1 M 9.1 M 9.1 M 9.1 M 9.1 M 9.1 M 9.1 M 922 K 200 K 200 K 200 K 200 K 200 K 100 K 100 K 100 K 100 K 46 K 32 K 11 K 35 K 32 K 19 K 16 K 13 K 12 K 8 K - 26 - - - - - - - - - -

Accounts Payables

7.61 M 9.42 M 8.39 M 21.2 M 10.1 M 11.6 M 12.7 M 15.2 M 13.5 M 10.1 M 11.9 M 14.6 M 9.04 M 11.8 M 12.6 M 18 M 19.7 M 24.9 M 19.5 M 33.6 M 28.8 M 42 M 30.5 M 41.3 M 40.4 M 29.4 M 54.4 M 39.2 M 64.4 M 19.3 M 15.2 M 42.8 M 12.7 M 4.8 M 17.9 M 7 M 8.7 M 10.2 M 15.1 M 2.04 M 8.52 M 5.14 M 2.42 M 2.31 M 5.27 M 2.41 M 4.33 M 2.02 M 3.03 M 1.49 M 2.08 M 714 K 714 K 714 K 714 K - - - - - - - -

Accounts Receivables

36.4 M 53.5 M 62.5 M 47 M 66.2 M 72.8 M 61.5 M 34.4 M 32.2 M 29.8 M 26.6 M 39.3 M 22.6 M 19.6 M 18.7 M 40.3 M 23.3 M 82 M 65.4 M 51.6 M 49.7 M 35 M 35.2 M 26.9 M 24.5 M 39.1 M 105 M 38.9 M 29.7 M 28.9 M 48.4 M 16.7 M 688 K 132 K 35.9 M 34.2 M 34.2 M 34.2 M 34.2 M 33.8 M - - - - 14 K 48 K 74 K 48 K 57 K 114 K 119 K 135 K 135 K 135 K 135 K - - - - - - - -

Total Inventories

18.7 M 13 M 13 M 15.6 M 18.6 M 16.7 M 19.7 M 16.2 M 20.5 M 23.9 M 25.5 M 15.7 M 18.4 M 20.9 M 20.4 M 21.6 M 45.2 M 40.2 M 41.1 M 36.6 M 33.7 M 37.9 M 44.8 M 61 M 88.2 M 105 M 112 M 116 M 116 M 122 M 115 M 114 M 114 M 114 M 114 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Cash Flow Statement is one of the three key financial reports of the company Akebia Therapeutics, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Biotechnology sector

Issuer Price % 24h Market Cap Country
Cassava Sciences Cassava Sciences
SAVA
- - $ 110 M usaUSA
Selecta Biosciences Selecta Biosciences
SELB
- -8.69 % $ 126 M usaUSA
Sangamo Therapeutics Sangamo Therapeutics
SGMO
- - $ 50.4 M usaUSA
Salarius Pharmaceuticals Salarius Pharmaceuticals
SLRX
- - $ 2.64 M usaUSA
Sensei Biotherapeutics Sensei Biotherapeutics
SNSE
- - $ 17.5 M usaUSA
Sonnet BioTherapeutics Holdings Sonnet BioTherapeutics Holdings
SONN
- - $ 826 K usaUSA
Synthetic Biologics Synthetic Biologics
SYN
- 1.32 % $ 16.2 M usaUSA
Synlogic Synlogic
SYBX
- - $ 7.07 M usaUSA
Virios Therapeutics, LLC Virios Therapeutics, LLC
VIRI
- 2710.01 % $ 72.9 M usaUSA
Vallon Pharmaceuticals Vallon Pharmaceuticals
VLON
- -6.47 % $ 5.76 M usaUSA
Vaxart Vaxart
VXRT
- -25.06 % $ 46.3 M usaUSA
XOMA Corporation XOMA Corporation
XOMA
- - $ 485 M usaUSA
Repare Therapeutics Repare Therapeutics
RPTX
- - $ 112 M canadaCanada
Sesen Bio Sesen Bio
SESN
- 7.29 % $ 127 M usaUSA
Windtree Therapeutics Windtree Therapeutics
WINT
- - $ 26.8 M usaUSA
Trean Insurance Group Trean Insurance Group
TIG
- - $ 316 M usaUSA
SQZ Biotechnologies Company SQZ Biotechnologies Company
SQZ
- 57.95 % $ 12.8 M usaUSA
MEI Pharma MEI Pharma
MEIP
- 10.43 % $ 20.5 M usaUSA
Palatin Technologies Palatin Technologies
PTN
- - $ 13 M usaUSA
ММЦБ ММЦБ
GEMA
- - - russiaRussia
Lyra Therapeutics Lyra Therapeutics
LYRA
- - $ 24.9 M usaUSA
Промомед Промомед
PRMD
- - - russiaRussia
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
ESSA Pharma ESSA Pharma
EPIX
- - $ 8.86 M canadaCanada
Generation Bio Co. Generation Bio Co.
GBIO
- - $ 344 M usaUSA
Clearside Biomedical Clearside Biomedical
CLSD
- - $ 25.3 M usaUSA
Merus N.V. Merus N.V.
MRUS
- - $ 5.78 B niderlandNiderland
RAPT Therapeutics RAPT Therapeutics
RAPT
- - $ 2.36 B usaUSA
Annexon Annexon
ANNX
$ 3.11 -8.94 % $ 482 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Galapagos NV Galapagos NV
GLPG
- - $ 1.83 B belgiumBelgium
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
- -4.36 % $ 27 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Galmed Pharmaceuticals Ltd. Galmed Pharmaceuticals Ltd.
GLMD
$ 4.63 21.05 % $ 20 M israelIsrael
Achieve Life Sciences Achieve Life Sciences
ACHV
$ 6.78 0.89 % $ 296 M usaUSA
Leap Therapeutics Leap Therapeutics
LPTX
- 368.57 % $ 41.9 M usaUSA
Lumos Pharma Lumos Pharma
LUMO
- - $ 35.3 M usaUSA
Gamida Cell Ltd. Gamida Cell Ltd.
GMDA
- -18.25 % $ 5.04 M israelIsrael
Axcella Health Axcella Health
AXLA
- -16.42 % $ 249 M usaUSA
Metacrine Metacrine
MTCR
- - $ 24.2 M usaUSA
Zealand Pharma A/S Zealand Pharma A/S
ZEAL
- 0.52 % $ 821 M danmarkDanmark
Myovant Sciences Ltd. Myovant Sciences Ltd.
MYOV
- -0.04 % $ 2.62 B usaUSA
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
- -74.18 % $ 955 K usaUSA
Idera Pharmaceuticals Idera Pharmaceuticals
IDRA
- -23.04 % $ 26.6 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Verona Pharma plc Verona Pharma plc
VRNA
- - $ 69.7 B britainBritain